Shopping Cart 0
Cart Subtotal
USD 0

Nattopharma ASA (NATTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Nattopharma ASA (Nattopharma) is a pharmaceutical company that develops and sells vitamin K2 for health care industries. The company's MenaQ7, a vitamin K2 as menaquinone-7 for bone and cardiovascular health and children's health. Its MenaQ7 varieties are suitable for vegans and vegetarians, free from gluten, dairy, and other known allergens. Nattopharma develops products for supplement, health care and functional food markets. The company provides services such as marketing and sales support, clinical chemistry testing, and contract manufacturing services. It collaborates with academic institutions and research facilities for its research activities. The company has presence throughout Norway. Nattopharma is headquartered in Oslo, Norway.

Nattopharma ASA (NATTO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nattopharma ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nattopharma ASA, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Nattopharma Enters into Distribution Agreement with Glanbia Nutritionals for MenaQ7 11

Nattopharma Enters into Distribution Agreement with Glanbia Nutritionals 12

Licensing Agreements 13

PharmaCo to Enter into Licensing Agreement with Nattopharma 13

Equity Offering 14

Nattopharma Raises USD1 Million in Private Placement of Shares 14

NattoPharma to Raise Funds through Rights Offering of Shares 15

NattoPharma to Raise Funds through Public Offering of Shares 16

NattoPharma Raises USD3.8 Million in Right Issue of Shares 17

NattoPharma Completes Rights Issue Of Shares For USD 4 Million 18

Acquisition 19

Bohan & Co Acquires Minority Stake in NattoPharma for USD0.37 Million 19

Nattopharma Acquires 34% Stake In VitaSynth 20

Nattopharma ASA-Key Competitors 21

Nattopharma ASA-Key Employees 22

Nattopharma ASA-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

May 09, 2018: NattoPharma market update 24

Feb 08, 2018: NATTO: Second Half And Preliminary Full Year 2017 Earnings Release 25

Aug 16, 2017: NattoPharma Interim Report First 6 Months 2017 26

Feb 08, 2017: NATTO: 4th Quarter and Full Year 2016 earnings release 28

Corporate Communications 29

Aug 22, 2018: Nattopharma apply for delisting from NASDAQ First North 29

Jun 05, 2018: NattoPharma organizational changes for growth 30

Feb 08, 2018: Natto: Enhanced Management Structure Aligned With Focused Business Unit Strategy 31

Government and Public Interest 32

Apr 28, 2017: NattoPharma Awarded Grant from Norwegian Research Council 32

Mar 21, 2017: NattoPharma Research Network Receives 4MEUR Research Grant 33

Feb 07, 2017: NattoPharma Named Partner For Horizon 2020 EU Research Grant 34

Product News 35

Nov 28, 2017: Exciting New Nattopharma Partnerships & Launch In China 35

Sep 21, 2017: NattoPharma: MenaQ7 Full Spectrum Vitamin K2 to Launch at SupplySide West 36

Aug 16, 2017: MenaQ7 Vitamin K2 Again Shown to Inhibit Hardening of Arteries: New Study 37

Jul 06, 2017: NattoPharma Announces Exciting New Product Launch in Brazil 38

Mar 14, 2017: New MenaQ7/Omega-3 Product By Wiley's Finest: NattoPharma Announces 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Nattopharma ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nattopharma ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nattopharma ASA, Deals By Therapy Area, 2012 to YTD 2018 9

Nattopharma ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nattopharma Enters into Distribution Agreement with Glanbia Nutritionals for MenaQ7 11

Nattopharma Enters into Distribution Agreement with Glanbia Nutritionals 12

PharmaCo to Enter into Licensing Agreement with Nattopharma 13

Nattopharma Raises USD1 Million in Private Placement of Shares 14

NattoPharma to Raise Funds through Rights Offering of Shares 15

NattoPharma to Raise Funds through Public Offering of Shares 16

NattoPharma Raises USD3.8 Million in Right Issue of Shares 17

NattoPharma Completes Rights Issue Of Shares For USD 4 Million 18

Bohan & Co Acquires Minority Stake in NattoPharma for USD0.37 Million 19

Nattopharma Acquires 34% Stake In VitaSynth 20

Nattopharma ASA, Key Competitors 21

Nattopharma ASA, Key Employees 22

Nattopharma ASA, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Nattopharma ASA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.